Warrick P, Bance M, Rutka J
Department of Otolaryngology, The Toronto Hospital, Ontario, Canada.
Am J Otol. 1999 Nov;20(6):758-62.
To determine the risk of loss of useful hearing in the absence of tumor growth among patients undergoing conventional management of acoustic neuroma.
Tertiary referral center.
Retrospective case review.
Ten patients (12 ears) were identified having a period of no tumor growth of at least 6 months (19.0+/-12.8 months), and for whom at least two audiograms were available in this period.
None.
Loss of useful hearing defined using 70% speech discrimination score (SDS) and 30 dB pure tone average (PTA) (70/30), or 50% SD and 50 dB PTA (50/50) criteria.
Three of seven (43%) ears with useful hearing using the 70/30 rule and two of eight ears (25%) using the 50/50 rule lost this useful hearing.
There is a significant risk of useful hearing loss with conservative management of nongrowing acoustic neuromas.
确定在接受听神经瘤常规治疗的患者中,在肿瘤未生长的情况下有用听力丧失的风险。
三级转诊中心。
回顾性病例审查。
确定10例患者(12耳)有至少6个月(19.0±12.8个月)的肿瘤无生长期,且在此期间至少有两次听力图。
无。
使用70%言语辨别得分(SDS)和30分贝纯音平均听阈(PTA)(70/30)或50% SDS和50分贝PTA(50/50)标准定义的有用听力丧失。
按照70/30规则,7耳中有3耳(43%)有有用听力,按照50/50规则,8耳中有2耳(25%)有有用听力,但这些耳均丧失了有用听力。
对于非生长性听神经瘤进行保守治疗时,有用听力丧失的风险很大。